



**For Immediate Release**

**Xcellerex Welcomes ISPE Japan Dignitaries for  
Tour of New FlexFactory® Biomanufacturing Facility**

*Japanese pharma and biopharma leaders  
visit state-of-the-art operation*

**Marlborough, MA – February 7, 2011** - Xcellerex, Inc. announced today that it hosted 20 members of the ISPE Japan Affiliate during the group's recent visit to the Boston area. The group, which included members of the ISPE Japan Board of Directors, arranged the visit to assess the recently completed FlexFactory facility at Xcellerex's Marlborough, MA headquarters.

ISPE Japan Affiliate Head of Secretariat Shigaru Nakamura commented, "We were pleased to witness the newly completed FlexFactory suite first-hand during our visit. FlexFactory represents a very interesting concept for the future of biomanufacturing, and we were given the unique opportunity to enter the facility and gain a deeper understanding of how it operates."

Xcellerex constructed the new FlexFactory facility to respond to the surge in customer interest in the platform. According to Xcellerex Senior Director of Global Marketing Ken Clapp, "This new plant enables our biomanufacturing services group to support the increased demand for transitional biomanufacturing that we offer to help speed client deployments of their new FlexFactory installations. Further, as this meeting with our visitors from Japan illustrates, the facility provides a working showcase to demonstrate FlexFactory design and capability to the many customers who have expressed interest in the platform for their next capacity investment."

Clapp also noted, "The timeline in which we brought this cGMP facility online dramatically underscores the leap in deployment speed FlexFactory enables. On Memorial Day, this space was the employee cafeteria. By Labor Day, construction was complete, and by Columbus Day, we were planning our first cGMP run."

The new facility features a single suite with 2,000 liter Xcellerex XDR single-use bioreactor, along with an XDR-50L and -200L for scale up, and modular single-use downstream unit operations through bulk-product. The facility also includes dedicated inoculation; media prep and buffer prep rooms.

-more-

**About FlexFactory**

Xcellerex's FlexFactory is an innovative, portable biomanufacturing platform, based on the innovative application of (1) single-use technologies; (2) controlled environmental modules (CEMs); and (3) advanced and proven process automation including electronic batch records. The FlexFactory effectively eliminates clean- and steam-in-place requirements and clean room infrastructure; greatly simplifies facility design, reducing manufacturing footprint and capital investment; and creates breakthrough gains in operating efficiency, flexibility and environmental friendliness.

**About Xcellerex, Inc.**

Xcellerex is commercializing turnkey biomanufacturing solutions that transform the speed and economics of producing therapeutic proteins, including biosimilars and vaccines. The company's FlexFactory® is a complete modular and portable production train based on single-use technologies, advanced process automation, and compact clean room architecture.

FlexFactory allows deployment of GMP manufacturing capacity more rapidly and at greatly reduced costs compared with traditional facilities. Through its BridgeSourcing™ services, Xcellerex manufactures a partner's biomolecules while the partner prepares for commissioning of its own new FlexFactory. When the partner's facility is ready, Xcellerex deploys its TransPlant™ process to install, validate and train partner personnel in their own FlexFactory. This parallel-path model both accelerates time to clinical and commercial manufacturing and allows partners to manage the development and market risks associated with adding manufacturing capacity.

Xcellerex also leverages its proprietary single use technologies through the sale of XDR bioreactors, XDM Quad Mixers, and related single-use assemblies. To date, more than 20 therapeutic proteins and vaccines have been manufactured for clinical trials using Xcellerex technology.

Based in Marlborough, Massachusetts, Xcellerex is backed by an experienced management team and top-tier venture investors including Kleiner Perkins Caufield & Byers, VantagePoint Venture Partners and SCG Capital. For more information, please visit the company's website at <http://www.xcellerex.com>

#####

**Contacts:**

Xcellerex, Inc.  
Kanchan Deshpande  
Marketing Specialist  
508-480-9235 ext. 475  
kdeshpande@xcellerex.com